Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Επικοινωνία Submitted by Δημήτρης Σπάχος on Δευ, 05/04/2015 - 10:28
